[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 482
Citations 0
Clinical Trials Update
May 26, 2015

High-Dose Novel Ebola Vaccine Immunogenic and Safe

JAMA. 2015;313(20):2015. doi:10.1001/jama.2015.4358

A novel recombinant adenovirus type-5 vector-based Ebola vaccine based on the 2014 Zaire Guinea Ebola strain, which is responsible for the current Ebola epidemic, elicited a robust immune response in recipients, according to the first phase 1 trial of the vaccine. (Zhu F-C et al. Lancet. doi:10.1016/S0140-6736(15)60553-0 [published online March 24, 2015]).

The trial, conducted in China, randomly assigned 120 healthy Chinese adults to receive placebo or a low dose or high dose of the vaccine. Twenty-eight days after vaccination, 38 of 40 participants in the low-dose group and all 40 of those in the high-dose group had a positive immune response to the vaccine, with the magnitude of the immune response being dose-dependent. No specific immune response was recorded in the placebo group, and no serious adverse events were reported in any group.

First Page Preview View Large
First page PDF preview
First page PDF preview
×